Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis

Abstract

There is uncertain result with regard to the use of inhalation or instillation steroids to prevent bronchopulmonary dysplasia in preterm infants. This meta-analysis was designed to evaluate the efficacy and safety of early airway administration (within 2 days after birth) of corticosteroids and pulmonary surfactant (PS) for preventing bronchopulmonary dysplasia (BPD) in premature infants with neonatal respiratory distress syndrome (NRDS). The related studies were retrieved in PubMed, EMBASE, the Cochrane Library, Clinical Trial, CNKI, Wanfang and VIP Database from inception to August 2018. Two reviewers independently screened the studies to ensure that all patients with diagnosis of NRDS were enrolled to studies within 1 day after birth, assessed the quality of included studies by GRADEpro system and extracted the data for review. The meta-analysis was performed by RevMan 5.2 software. A subgroup analysis about inhaled corticosteroid (ICS) delivery method was made between ICS inhalation subgroup [inhalation of ICS by nebulizer or metered dose inhaler (MDI)] and ICS intratracheal instillation subgroup (PS used as a vehicle). Eight randomized controlled trials were enrolled in the meta-analysis, 5 trials of which stated the randomized method, grouping and blinded method, and the follow-up procedures were reported. GRADEpro system showed high quality of 4 trials (5 articles), and the rest 4 trials had moderate quality. Meta-analysis showed that the incidence of BPD was decreased in ICS group, the relative risk (RR) was 0.56 (95% CI: 0.42–0.76), and similar trends were found in ICS inhalation subgroup and ICS intratracheal instillation subgroup, with the corresponding RR being 0.58 (95% CI: 0.41–0.82) and 0.47 (95% CI: 0.24–0.95) respectively. ICS could also significantly reduce the mortality risk as compared with placebo control group (RR: 0.67; 95% CI: 0.45–0.99), with RR of ICS inhalation subgroup and ICS intratracheal instillation subgroup being 0.81 (95% CI: 0.34–1.94) and 0.64 (95% CI: 0.41–0.99) respectively. Moreover, the percentage of infants using PS more than one time was lower in ICS group than in the placebo control group, with the RR and 95% CI being 0.55 (95% CI: 0.45–0.67), and that in ICS intratracheal instillation subgroup lower than in ICS inhalation subgroup (RR: 0.56; 95% CI: 0.45–0.69, and RR: 0.35; 95% CI: 0.08–1.52 respectively). There was no significant difference in the incidence of infection or retinopathy of prematurity and neuro-motor system impairment between ICS group and placebo control group, with the corresponding RR being 0.95 (95% CI: 0.59–1.52), 0.92 (95% CI: 0.62–1.38) and 1.13 (95% CI: 0.92–1.39), respectively. It was concluded that early administration of ICS and PS is an effective and safe option for preterm infants with NRDS in preventing BPD and reducing mortality, decreasing the additional PS usage, especially for the ICS intratracheal instillation subgroup. Furthermore, the appropriate dose and duration of ICS, combined use of inhalation or instillation of ICS with PS and the long-term safety of airway administration of corticosteroids need to be assessed in large trials.

References

[1] CarvalhoCG, SilveiraRC, ProcianoyRS. Ventilator-induced lung injury in preterm infants. Revista Brasileira De Terapia Intensiva, 2013, 25(4): 319-326

[2] YehTF, LinYJ, HsiehWS, et al.. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics, 1997, 100(4): e3-e3

[3] Collaborative Dexamethasone Trial Group.. Dexameth-asone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics, 1991, 88(3): 421-427

[4] CummingsJJ, D’EugenioDB, GrossSJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med, 1989, 320(23): 1505-1510

[5] Vermont Oxford Network Steroid Study Group.. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics, 2001, 108(3): 741-748

[6] YehTF, LinYJ, HuangCC, et al.. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics, 1998, 101(5): E7

[7] AveryGB, FletcherAB, KaplanM, et al.. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics, 1985, 75(1): 106-111

[8] YehTF, LinYJ, LinHC, et al.. Outcome at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med, 2004, 350(13): 1304-1313

[9] GriggJ, ArnonS, JonesT, et al.. Delivery of therapeutic aerosols to intubated babies. Arch Dis Child, 1992, 67(1): 25-30

[10] ColeCH, ColtonT, ShahBL, et al.. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med, 1999, 340(13): 1005-1010

[11] FujiwaraT, ChidaS, WatabeY, et al.. Artificial surfactant therapy in hyaline membrane disease. Lancet, 1980, 1(8159): 55-59

[12] FerraraTB, HoekstraRE, JohnsonP, et al.. Localization of surfactant in neonatal lung after exogenous administration. J Pediatr, 1987, 111(3): 463-466

[13] TamD, Von ArnimV, MckinleyGH, et al.. Marangoni convection in droplets on superhydrophobic surfaces. J Fluid Mechan, 2009, 624: 101

[14] FajardoC, LevinD, GarciaM, et al.. Surfactant versus saline as a vehicle for corticosteroid delivery to the lungs of ventilated rabbits. Pediatr Res, 1998, 43(4): 542-547

[15] KharaschVS, SweeneyTD, FredbergJ, et al.. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis, 1991, 144(4): 909-913

[16] KuoHT, LinHC, TsaiCH, et al.. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr, 2010, 156(4): 537-541

[17] YehTF, LinHC, ChangCH, et al.. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics, 2008, 121(5): e1310-e1318

[18] SadeghniaA, BeheshtiBK, MohammadizadehM. The effect of inhaled budesonide on the prevention of chronic lung disease in premature neonates with respiratory distress syndrome. Int J Prev Med, 2018, 9: 15

[19] YehTF, ChenCM, WuSY, et al.. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respirat Crit Care Med, 2016, 193(1): 86-95

[20] ZimmermanJJ, GabbertD, ShivpuriC, et al.. Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia. Pediatr Crit Care Med, 2000, 1(2): 140-145

[21] CaoYY, YaoG, WangY, et al.. Aerosol Inhalation of Budesonide and Pulmonary Surfactant to Prevent Bronchopulmonary Dysplasia. J Pediatr Pharmacy, 2018, 24(03): 25-29

[22] KeH, LiZK, YuXP, et al.. Efficacy of different preparations of budesonide combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome: a comparative analysis. Zhongguo Dang Dai Er Ke Za Zhi (Chinese), 2016, 18(5): 400-404

[23] PanJ, ChenMW, NiWQ, et al.. Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants. Zhongguo Dang Dai Er Ke Za Zhi (Chinese), 2017, 19(2): 137-141

[24] DengLJ, PengHB, GongXQ. Effect of budesonide combined with pulmonary surfactant on severe respiratory distress syndrome in bronchopulmonary dysplasia. Chin J Neonatol (Chinese), 2017, 32(5): 361-364

[25] SchulzKF, AltmanDG, MoherD. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med, 2010, 8(1): 18

[26] BhandariA, PanitchH. An update on the post-NICU discharge management of bronchopulmonary dysplasia. Semin Perinatol, 2018, 42(7): 471-477

[27] NagiubM, KanaanU, SimonD, et al.. Risk factors for development of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review and meta-analysis. Paediatr Respirat Rev, 2017, 23: 27-32

[28] MerzU, KusenbachG, HäuslerM, et al.. Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Neonatology, 1999, 75(1): 46-53

[29] OnlandW, OffringaM, van KaamA. Late (=7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev, 2012, 4: CD2311

[30] VenkataramanR, KamaluddeenM, HasanSU, et al.. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and metaanalysis. Pediatr Pulmonol, 2017, 52(7): 968-975

[31] ZhangZQ, ZhongY, HuangXM, et al.. Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis. BMC Pulmon Med, 2017, 17(1): 207

[32] ZengL, TianJ, SongF, et al.. Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Arch Dis Child Fetal Neonatal Ed, 2018, 103(6): F506-F511

[33] YuZW, ZhangJH. Effect of inhaled budesonide on surfactant protein expression in asthmatic mice. Allergy Asthma Proc, 2008, 29(5): 486-492

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology